tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Vamil Divan, 225 are a BUY (64.29%), 114 are a HOLD (32.57%), 11 are a SELL (3.14%).
Analyst Vamil Divan, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 58.68% that have a potential upside of 29.65% achieved within 239 days.
Vamil Divan’s has documented 701 price targets and ratings displayed on 41 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ABBV, AbbVie at 17-Apr-2025.
Analyst best performing recommendations are on KRTX (KARUNA THERAPEUTICS).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) at 8/9/2022. The price target of $276 was fulfilled within 3 days with a profit of $47.55 (20.81%) receiving and performance score of 69.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$214
$27.94 (15.02%)
$214
15 days ago
(17-Apr-2025)
23/25 (92%)
$41.01 (23.71%)
431
Buy
$241
$54.94 (29.53%)
$239
23 days ago
(09-Apr-2025)
12/17 (70.59%)
$61.16 (34.01%)
526
Buy
$240
$53.94 (28.99%)
$210
1 months 27 days ago
(05-Mar-2025)
7/8 (87.5%)
$28.46 (13.45%)
474
Hold
$223
$36.94 (19.85%)
$191
1 months 28 days ago
(04-Mar-2025)
3/4 (75%)
$15.71 (7.58%)
443
Buy
$217
$30.94 (16.63%)
$211
2 months 29 days ago
(03-Feb-2025)
2/3 (66.67%)
$26.86 (14.13%)
103
Which stock is Vamil Divan is most bullish on?
Which stock is Vamil Divan is most reserved on?
What Year was the first public recommendation made by Vamil Divan?
